-
2023-508926-91-00
5
2019-12-05
Stage IV childhood renal tumour with pulmonary +/- non-pulmonary
metas
-
2023-507883-38-00
5
2019-11-18
Systemic Juvenile Idiopathic Arthritis
-
2023-506131-15-00
5
2019-09-10
Juvenile Idiopathic Arthritis
-
2023-508101-24-00
5
2019-08-01
Lymphoblastic lymphoma
-
2024-514409-78-01
9
2019-07-26
relapsed / refractory or progressive high risk malignant disease
-
2023-509819-87-00
6
2019-07-18
hypogonadism, T2DM, prediabetes, overweight, obesity
-
2024-513734-38-00
5
2019-07-03
Prevention of breast cancer in women with a BRCA1 germline mutation
-
2024-512444-29-00
5
2019-05-07
patients who will undergo kidney, liver or kidney-pancreatic
transplan
-
2024-512830-13-00
3
2019-03-25
anorexia nervosa
-
2023-504201-36-00
10
2018-12-21
Defined by parent protocol. The study will enroll all adult and paedia
-
2024-518808-43-00
1
2018-10-22
brain tumors
-
2022-501254-10-00
5
2018-08-24
Advanced tumors
-
2024-512681-34-00
3
2018-06-04
Healthy volunteers and critically ill patients
-
2024-516110-38-00
5
2018-03-06
Hepatoblastoma and Hepatocellular Carcinoma
-
2024-513526-27-00
4
2018-02-23
secondary or quaternary peritonitis
-
2024-517875-19-00
1
2017-10-12
Investigation in healthy volunteers and dementia patients (Alzheimers
-
2024-517260-39-00
3
2017-09-15
Combustion
-
2023-508128-37-00
5
2017-07-19
All patients who have been treated with Novartis or Penn CAR T-cell th
-
2024-513637-20-00
4
2017-03-24
Locally Advanced/Metastatic Squamous Cell Carcinoma of the Skin
-
2024-514556-32-00
5
2017-02-15
Adult critically ill patients with severe vitamin D deficiency
-
2023-506987-15-00
9
2016-11-17
Metastatic Castration-Resistant Prostate Cancer
-
2024-516550-21-00
1
2015-06-26
cancer
-
2024-512222-28-00
10
2015-06-02
Newly diagnosed with an intracranial or spinal ependymoma (all WHO gra
-
2024-516078-31-00
10
2015-05-05
Recurrent and Primary Refractory Ewing Sarcoma